Screening study for CLN2 disease in 6-year-olds
Treatments studied
Part of Brain & nervous system, Genetic & congenital clinical trials.
This study is screening children for a rare genetic condition called CLN2 disease. It looks for signs like seizures, speech loss, and movement problems to find out how common this condition is among 6-year-olds.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be exactly 6 years old.
- Your child must have had at least one seizure that started for no clear reason.
- Your child must have a problem with speech or movement, or show certain brain changes on an EEG or MRI.
- The seizures and problems cannot be due to birth injury, head trauma, or a brain defect.
- Your child must not have been diagnosed with CLN2 disease before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at people with CLN3 and other related forms of NCL (a childhood brain-wasting illness) to better describe symptoms and disease changes over time. You may be followed with regular check-ins, medical records, and sometimes NIH visits or sample collection.
This study looks at how children’s development progresses in CLN2 disease caused by a specific enzyme problem (TPP1). It may help doctors better understand outcomes and guide future care for children with this diagnosis.
This trial tracks how Batten disease (NCL) affects the body and how symptoms change over time. If you have a confirmed genetic (molecular) diagnosis—especially CLN2 with Brineura treatment—it may help researchers understand disease patterns and care needs.
This study tests a new gene therapy, TTX-381, given as an eye injection to slow or stop vision loss in children with CLN2 disease. It is for children who are already receiving enzyme replacement therapy and are in a stage of rapid vision decline.
This study tests an investigational drug called PLX-200 in children with four rare lysosomal storage diseases. The goal is to see if it is safe and might slow down the disease.
This trial is creating a registry (a secure database) for people with a confirmed genetic diagnosis of NCL (Batten disease). The goal is to collect information over time to help researchers understand the disease better and plan future treatments.
Hear when a new Neuronal Ceroid Lipofuxinosis Type2 (CLN2) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.